Influence of Cytochrome P450 (CYP) 3A5 Polymorphisms on the Pharmacokinetics of Lansoprazole Enantiomers in CYP2C19 Extensive Metaboliser Renal Transplant Recipients

By Miura Masatomo  

Clinical Drug Investigation, Vol. 27, Iss. 4, 2007-01 ,pp. : 251-258

Adis International

Access to resources Recommend Favorite

Population Pharmacokinetics and Bayesian Estimation of Tacrolimus Exposure in Renal Transplant Recipients on a New Once-Daily Formulation

By Benkali Khaled  

Clinical Pharmacokinetics, Vol. 49, Iss. 10, 2010-10 ,pp. : 683-692

Adis International

Access to resources Recommend Favorite

Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients

By Miura Masatomo   Satoh Shigeru   Kagaya Hideaki   Saito Mitsuru   Numakura Kazuyuki   Tsuchiya Norihiko   Habuchi Tomonori  

Pharmacogenomics, Vol. 12, Iss. 7, 2011-07 ,pp. : 977-984

Future Medicine

Access to resources Recommend Favorite

The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients

By de Jonge Hylke   Metalidis Christoph   Naesens Maarten   Lambrechts Diether   Kuypers Dirk RJ  

Pharmacogenomics, Vol. 12, Iss. 9, 2011-09 ,pp. : 1281-1291

Future Medicine

Access to resources Recommend Favorite

Tacrolimus Once-Daily Formulation in the Prophylaxis of Transplant Rejection in Renal or Liver Allograft Recipients: A Viewpoint by Sander Florman

By Florman Sander  

Drugs, Vol. 67, Iss. 13, 2007-01 ,pp. : 1944-1945

Adis International

Access to resources Recommend Favorite